Katja M Gist1,2, Stuart L Goldstein3, Julia Wrona4, Jeffrey A Alten5, Rajit K Basu6, David S Cooper7, Danielle E Soranno8,9, Jane Duplantis8,9, Christopher Altmann10, Zhiqian Gao11, Sarah Faubel10. 1. Children's Hospital Colorado-The University of Colorado, 13123 E 16th Ave, Aurora, CO, 80045, USA. katja.gist@childrenscolorado.org. 2. The Heart Institute, Children's Hospital Colorado, 13123 E 16th Ave, B100, Aurora, CO, 80045, USA. katja.gist@childrenscolorado.org. 3. Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 7022, Cincinnati, OH, 45229, USA. 4. The Heart Institute, Children's Hospital Colorado, 13123 E 16th Ave, B100, Aurora, CO, 80045, USA. 5. Pediatric Critical Care Medicine, Children's of Alabama-University of Alabama, WIC 1799 6th Ave S, Suite 9100 176 F, Birmingham, AL, 35233, USA. 6. Pediatric Critical Care Medicine, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 2005, Cincinnati, OH, 45229, USA. 7. The Heart Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 2003, Cincinnati, OH, 45229, USA. 8. Children's Hospital Colorado-The University of Colorado, 13123 E 16th Ave, Aurora, CO, 80045, USA. 9. The Kidney Center, Children's Hospital Colorado-The University of Colorado, 13123 E 16th Ave, Aurora, CO, 80045, USA. 10. Department of Internal Medicine, Division of Renal Disease and Hypertension, University of Colorado Anschutz Medical Campus, 12700 E 19th Ave, Box C281, Aurora, CO, 80045, USA. 11. Heart Institute Research Core, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC, Cincinnati, OH, 45229, USA.
Abstract
BACKGROUND: Tissue inhibitor metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP-7) are cell-cycle arrest biomarkers that have been shown to be predictive of acute kidney injury (AKI) in critically ill adults. AKI affects a large proportion (40%) of children following cardiac surgery. The aim of this study was to describe the kinetics of TIMP-2*IGFBP-7 and test its ability to predict AKI in infants following cardiac surgery. METHODS: A multicenter prospective study was performed in infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) from October 2013 to January 2015. Urine samples were obtained at baseline and at 2, 6, 12, 24, 48 and 72 h after CPB initiation. TIMP-2*IGFBP-7 concentration was measured in urine samples using the Astute 140® meter to determine a risk score for AKI. This risk score is the product of TIMP-2 (ng/mL) and IGFBP-7 (ng/mL) divided by 1000. RESULTS: A total of 94 infants with a mean age of 154.2 ± 85.7 days were enrolled in the study, of whom 31 (33%) subsequently developed AKI. The mean time to AKI diagnosis was 25 ± 7 h after CPB initiation. The concentration of TIMP-2*IGFBP-7 was significantly higher in patients with AKI at 12 h after CPB initiation relative to baseline (p = 0.006). At 12 h after CPB initiation patients with a TIMP-2*IGFBP-7 concentration of ≥0.78 had a threefold higher odds of developing AKI than those with a TIMP-2*IGFBP-7 concentration of < 0.78 (95% confidence interval 1.47-6.11, p = 0.001). CONCLUSION: These results demonstration that TIMP-2*IGFBP-7 concentration can be used in infants to predict subsequent serum creatinine-defined AKI following CPB.
BACKGROUND:Tissue inhibitor metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP-7) are cell-cycle arrest biomarkers that have been shown to be predictive of acute kidney injury (AKI) in critically ill adults. AKI affects a large proportion (40%) of children following cardiac surgery. The aim of this study was to describe the kinetics of TIMP-2*IGFBP-7 and test its ability to predict AKI in infants following cardiac surgery. METHODS: A multicenter prospective study was performed in infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) from October 2013 to January 2015. Urine samples were obtained at baseline and at 2, 6, 12, 24, 48 and 72 h after CPB initiation. TIMP-2*IGFBP-7 concentration was measured in urine samples using the Astute 140® meter to determine a risk score for AKI. This risk score is the product of TIMP-2 (ng/mL) and IGFBP-7 (ng/mL) divided by 1000. RESULTS: A total of 94 infants with a mean age of 154.2 ± 85.7 days were enrolled in the study, of whom 31 (33%) subsequently developed AKI. The mean time to AKI diagnosis was 25 ± 7 h after CPB initiation. The concentration of TIMP-2*IGFBP-7 was significantly higher in patients with AKI at 12 h after CPB initiation relative to baseline (p = 0.006). At 12 h after CPB initiation patients with a TIMP-2*IGFBP-7 concentration of ≥0.78 had a threefold higher odds of developing AKI than those with a TIMP-2*IGFBP-7 concentration of < 0.78 (95% confidence interval 1.47-6.11, p = 0.001). CONCLUSION: These results demonstration that TIMP-2*IGFBP-7 concentration can be used in infants to predict subsequent serum creatinine-defined AKI following CPB.
Authors: Joshua J Blinder; Stuart L Goldstein; Vei-Vei Lee; Alixandra Baycroft; Charles D Fraser; David Nelson; John L Jefferies Journal: J Thorac Cardiovasc Surg Date: 2011-07-27 Impact factor: 5.209
Authors: Rajit K Basu; Michael Zappitelli; Lori Brunner; Yu Wang; Hector R Wong; Lakhmir S Chawla; Derek S Wheeler; Stuart L Goldstein Journal: Kidney Int Date: 2013-09-18 Impact factor: 10.612
Authors: Michael G Gaies; James G Gurney; Alberta H Yen; Michelle L Napoli; Robert J Gajarski; Richard G Ohye; John R Charpie; Jennifer C Hirsch Journal: Pediatr Crit Care Med Date: 2010-03 Impact factor: 3.624
Authors: Anna J Wetz; Eva M Richardt; Saskia Wand; Nils Kunze; Hanna Schotola; Michael Quintel; Anselm Bräuer; Onnen Moerer Journal: Crit Care Date: 2015-01-06 Impact factor: 9.097
Authors: Melanie Meersch; Christoph Schmidt; Hugo Van Aken; Jan Rossaint; Dennis Görlich; Dirk Stege; Edward Malec; Katarzyna Januszewska; Alexander Zarbock Journal: PLoS One Date: 2014-10-24 Impact factor: 3.240
Authors: Kevin Pilarczyk; Michaela Edayadiyil-Dudasova; Daniel Wendt; Ender Demircioglu; Jaroslav Benedik; Daniel Sebastian Dohle; Heinz Jakob; Fabian Dusse Journal: Ann Intensive Care Date: 2015-12-15 Impact factor: 6.925
Authors: Kianoush Kashani; Ali Al-Khafaji; Thomas Ardiles; Antonio Artigas; Sean M Bagshaw; Max Bell; Azra Bihorac; Robert Birkhahn; Cynthia M Cely; Lakhmir S Chawla; Danielle L Davison; Thorsten Feldkamp; Lui G Forni; Michelle Ng Gong; Kyle J Gunnerson; Michael Haase; James Hackett; Patrick M Honore; Eric A J Hoste; Olivier Joannes-Boyau; Michael Joannidis; Patrick Kim; Jay L Koyner; Daniel T Laskowitz; Matthew E Lissauer; Gernot Marx; Peter A McCullough; Scott Mullaney; Marlies Ostermann; Thomas Rimmelé; Nathan I Shapiro; Andrew D Shaw; Jing Shi; Amy M Sprague; Jean-Louis Vincent; Christophe Vinsonneau; Ludwig Wagner; Michael G Walker; R Gentry Wilkerson; Kai Zacharowski; John A Kellum Journal: Crit Care Date: 2013-02-06 Impact factor: 9.097
Authors: Phillip S Adams; Diana Vargas; Tracy Baust; Lucas Saenz; Wonshill Koh; Brian Blasiole; Patrick M Callahan; Aparna S Phadke; Khoa N Nguyen; Yuliya Domnina; Mahesh Sharma; John A Kellum; Joan Sanchez-de-Toledo Journal: Pediatr Crit Care Med Date: 2019-01 Impact factor: 3.624
Authors: Katja M Gist; David S Cooper; Julia Wrona; Sarah Faubel; Christopher Altmann; Zhiqian Gao; Bradley S Marino; Jeffrey Alten; Kristal M Hock; Tomoyuki Mizuno; Alexander A Vinks; Melanie S Joy; Michael F Wempe; Michael R Bennett; Stuart L Goldstein Journal: Ther Drug Monit Date: 2018-04 Impact factor: 3.681
Authors: Ana Flávia Lima Ruas; Gabriel Malheiros Lébeis; Nicholas Bianco de Castro; Vitória Andrade Palmeira; Larissa Braga Costa; Katharina Lanza; Ana Cristina Simões E Silva Journal: Pediatr Nephrol Date: 2021-11-30 Impact factor: 3.651
Authors: Dana Y Fuhrman; John A Kellum; Emily L Joyce; Yosuke Miyashita; George V Mazariegos; Armando Ganoza; James E Squires Journal: Pediatr Transplant Date: 2019-10-25